Description

Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).

Catalog No.

CSV03801

Host species

Homo sapiens

Species reactivity

Influenza A virus

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Concentration

1 mg/ml

Purity

>95% by SDS-PAGE.

Clonality

Monoclonal

Isotype

IgG1, lambda

Applications

Research Grade Diridavumab Biosimilar

Target

HA,Hemagglutinin

Purification

Protein A or G purified from cell culture supernatant.

Endotoxin level

Please contact with the lab for this information.

Expression system

Mammalian

Accession

P03455

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Alternative Names

CR-6261, CR6261, CAS: 1393659-46-5, Influenza Virus (Flu)

Note

For research use only. Not suitable for clinical or therapeutic use.